Sort   by:  
 Page size 
Proteomics,MultiomicsTranscriptional and translational regulatory responses to iron limitation in the globally distributed marine bacterium Candidatus Pelagibacter ubique
Investigation of the gene expression responses of Candidatus Pelagibacter ubique cultures to iron limitation in natural seawater media supplemented with a siderophore to chelate iron. Quantitative peptide mass spectrometry revealed that sfuC protein abundance increased 27-fold, despite an average de...
ORGANISM(S): Candidatus Pelagibacter Ubique (ncbitaxon:198252) 
2020-05-18 | MSV000085445 | MassIVE
UnknownComplete genome sequence of Erythrobacter litoralis HTCC2594.
Not available
S-EPMC2655494 | biostudies-literature
UnknownComplete genome sequence of Robiginitalea biformata HTCC2501.
Not available
S-EPMC2772462 | biostudies-literature
UnknownGenome sequence of the oligotrophic marine Gammaproteobacterium HTCC2143, isolated from the Oregon Coast.
Not available
S-EPMC2937397 | biostudies-literature
UnknownComplete genome sequence of Croceibacter atlanticus HTCC2559T.
Not available
S-EPMC2937408 | biostudies-literature
MetabolomicsSAR11 Cells Rely on Enzyme Multifunctionality to Transport and Metabolize a Range of Polyamine Compounds
In the ocean surface layer and cell culture, the polyamine transport protein PotD of SAR11 bacteria is often one of the most abundant proteins detected. Polyamines are organic cations at seawater pH produced by all living organisms and are thought to be an important component of dissolved organic ma...
2021-09-09 | MTBLS3146 | MetaboLights
UnknownSafety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Not available
S-EPMC4962457 | biostudies-literature
UnknownBig conductance calcium-activated potassium channel openers control spasticity without sedation.
Not available
S-EPMC5522996 | biostudies-literature
UnknownCOVID-19 Vaccine Response in People with Multiple Sclerosis.
Not available
S-EPMC8652739 | biostudies-literature
UnknownEvaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Not available
S-EPMC11409264 | biostudies-literature
Sort   by:  
 Page size